ampa receptor potentiators
Recently Published Documents


TOTAL DOCUMENTS

16
(FIVE YEARS 2)

H-INDEX

12
(FIVE YEARS 0)

2013 ◽  
Vol 56 (22) ◽  
pp. 9180-9191 ◽  
Author(s):  
Nandini C. Patel ◽  
Jacob Schwarz ◽  
Xinjun J. Hou ◽  
Dennis J. Hoover ◽  
Longfei Xie ◽  
...  

2010 ◽  
Vol 17 (30) ◽  
pp. 3575-3582 ◽  
Author(s):  
B. Pirotte ◽  
P. Francotte ◽  
E. Goffin ◽  
P. Fraikin ◽  
L. Danober ◽  
...  

2006 ◽  
Vol 103 (26) ◽  
pp. 10064-10067 ◽  
Author(s):  
S. Tomita ◽  
M. Sekiguchi ◽  
K. Wada ◽  
R. A. Nicoll ◽  
D. S. Bredt

2005 ◽  
Vol 27 (3) ◽  
pp. 243-248 ◽  
Author(s):  
Sanjay J Mathew ◽  
Kathryn Keegan ◽  
Lisa Smith

Recent evidence suggests that critical molecules in neurotrophic signaling cascades are long-term targets for currently available monoaminergic antidepressants. As chronic and severe mood disorders are characterized by impairments in neuronal resilience, pharmacological strategies that subserve a neuroprotective function might alter disorder pathophysiology and modify disease progression. Several promising approaches involve modulation of the glutamate neurotransmitter system, via post-synaptic receptor blockade or potentiation and presynaptic vesicular release inhibition. A focused review of the extant scientific literature was conducted, with a discussion of 3 compounds or classes of drugs currently undergoing clinical investigation: ketamine, riluzole, and AMPA receptor potentiators. Recent investigations in mood disordered patients suggest that the NMDA receptor antagonist ketamine might demonstrate rapid antidepressant properties. Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor. Open-label trials in treatment-resistant depression have yielded promising results. Likewise, AMPA receptor potentiators favorably impact neurotrophic factors as well as enhance cognition. CONCLUSIONS: Pharmacological approaches that modulate components of the glutamate system offer novel targets for severe, recurrent mood disorders. Controlled studies are necessary.


Sign in / Sign up

Export Citation Format

Share Document